An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients

Pain Physician

Volumn 13, Issue 3, 2010, Pages 273-281

  Pesce, Amadeo ^a   Rosenthal, Murray ^a   West, Robert ^a   West, Cameron ^a   Crews, Bridgit ^a   Mikel, Charles ^a   Almazan, Perla ^a   Latyshev, Sergey ^a  

^a Millennium Laboratories Research Institute   (United States)

Author keywords

Adherence monitoring; Benzodiazepines; Drug abuse; False negatives; Illicit drug use; Illicit drugs; Immunoassay; Liquid chromatography mass spectrometry; Opioids

Indexed keywords

ALPRAZOLAM; AMPHETAMINE; CANNABINOID; COCAINE; CODEINE; DEXTROPROPOXYPHENE; HYDROCODONE; HYDROMORPHONE; ILLICIT DRUG; LORAZEPAM; METHADONE; METHAMPHETAMINE; MORPHINE; NORDAZEPAM; NORPROPOXYPHENE; OXAZEPAM; TEMAZEPAM;

ARTICLE; CHRONIC PAIN; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG ABUSE; DRUG DEPENDENCE; DRUG SCREENING; DRUG URINE LEVEL; FALSE NEGATIVE RESULT; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; PATIENT COMPLIANCE; PRESCRIPTION; TANDEM MASS SPECTROMETRY; URINALYSIS; URINARY EXCRETION;

AUTOMATION; BENZODIAZEPINES; CHROMATOGRAPHY, LIQUID; COCAINE; COHORT STUDIES; FALSE NEGATIVE REACTIONS; HUMANS; IMMUNOASSAY; MEDICATION ADHERENCE; OSMOLAR CONCENTRATION; PAIN; SINGLE-BLIND METHOD; STREET DRUGS; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY;

EID: 77953338806     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Manchikanti L, Singh A. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008; 11: S63-88.
2. Manchikanti L, Damron KS, McManus C, Barnhill R. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: A prospective observational study. Pain Physician 2004; 7:431-437.
3. Kuehn B. Efforts aim to curb opioid deaths, injuries. JAMA 2009; 301:1213-1215.
4. Manchikanti L, Cash KA, Damron KS, Manchukonda R, Pampati V, McManus CD. Controlled substance abuse and illicit drug use in chronic pain patients: an evaluation of multiple variables. Pain Physician 2006; 9:215-226.
5. Manchikanti L, Manchukonda R, Pampati V, Damron KS Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short acting (hydrocodone) or long acting (methadone) opioids. Pain Physician 2005; 8:257-261.
6. Manchikanti L., Manchukonda R., Pampati V., Damron KS, Brandon DE, Cash KA, McManus CD. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician 2006; 9:123-129.
7. Trescot AM, Helm S, Hansen H, Benyamin, R, Glaser S, Adlaka R, Patel S, Manchikanti L. Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008; 11:S5-S62.
8. Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: Tools, techniques, and utility. Pain Physician 2008; 11:S155-S180.
9. Smith HS, Deer TR, Staats PS, Singh V, Sehgal N, Cordner H. Intrathecal drug delivery. Pain Physician 2008; 11:S89-S104.
10. Benyamin R, Trescot AM, Datta S, Buenaventura RM, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician 2008; 11:S105-S120.
11. Silverman S. Opioid induced hyperalgesia: Clinical implications for the pain practitioner. Pain Physician 2009; 2:679-684.
12. Manchikanti KN, Manchikanti L, Damron KS, Pampati V, Fellows B. Increasing deaths from opioid analgesics in the United States: An evaluation in an interventional pain management practice. J Opioid Manage 2008; 4:271-283.
13. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, Crosby AE, Paulozzi LJ. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300:2613-2620.
14. McLellan AT, Turner B. Prescription opioids, overdose deaths, and physician responsibility. JAMA 2008; 300:2613-2620.
15. Manchikanti L, Malla Y, Wargo BW, Cash KA, Pampati V, Damron KS, McManus CD, Brandon DE. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: A prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS). Pain Physician 2010; 13:E1-E22.
16. Gilbert JW, Wheeler GR, Mick GE, Storey BB, Herder SL, Richardson GB, Watts E, Gyarteng-Dakwa K, Marino BS, Kenney CM, Siddiqi M, Broughton PG. Urine drug testing in the treatment of chronic noncancer pain in a Kentucky private neuroscience practice: The potential effect of Medicare benefit changes in Kentucky. Pain Physician 2010; 13:187-194.
17. Gilbert JW, Wheeler GR, Mick GE, Storey BB, Herder SL, Richardson GB, Watts E, Gyarteng-Dakwa K, Marino BS, Kenney CM, Siddiqi M, Broughton PG. Importance of urine drug testing in the treatment of chronic noncancer pain: Implications of recent Medicare policy changes in Kentucky. Pain Physician 2010; 13:167-186.
18. Pesce A, West C, Rosenthal M, West R, Crews B, Mikel C, Almazan P, Latzshev S. Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician 2010; 13:?????
19. West R, Pesce A, West C, Crews B, Mikel C, Almazan P, Rosenthal M, Latyshev S. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population. Pain Physician 2010; 13:71-78.
20. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Mandatory Guidelines for Federal Workplace Drug Testing Programs: Notice. Federal Register, 2009; 73: 228.
21. Hammett-Stabler C, Pesce A, Cannon D. Urine drug screening in the medical setting. Clin Chim Acta 2002; 315:125-135.
22. White, RM, Black ML. Pain Management Testing Reference. AACC Press Washington, DC, 2008; pp 204-208
23. Wingert WE. Lowering cutoffs for initial and confirmation testing for cocaine and marijuana: Large-scale study of effects on the rates of drug-positive results. Clin Chem 1997; 43:100-103.
24. Valentine J, Middleton R, Sparks C. Identification of urinary benzodiazepines and their metabolites: Comparison of automated HPLC and GC-MS after immunoassay screening of clinical specimens. Journal of Analytical Toxicology 1996; 20:416-424.
25. Meatherrall R, Fraser AD. Comparison of four immunoassays for the detection of lorazepam in urine. Ther Drug Monit 1998; 20:673-675.
26. Fraser AD Psychotropic agents: The benzodiazepines. In Shaw LM, Kwong TC, Rosano TG, Orsolak PJ, Wolf BA, & Magnani B, Eds. The Clinical Toxicology Laboratory. Contemporary Practice of Poisoning Evaluation. AACC Press, Washington, DC, 2001.
27. Kurisaki E, Hayashida M, Nihira M, Ohno Y, Mashiko H, Okano T, Niwa S, & Hiraiwa K. Diagnostic performance of triage for benzodiazepines: Urine analysis of the dose of therapeutic cases. J Anal Toxicol 2005; 29:539-543.
28. Fraser AD, Zamecnik J. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther Drug Monit 2003; 25:723-727.
29. Hattab EM, Goldberger BA, Johannsen LM, Kindland PW, Ticino F, Chronister CW, Bertholf RL. Modification of screening immunoassays to detect sub-threshold concentrations of cocaine, cannabinoids, and opiates in urine: Use for detecting maternal and neonatal drug exposures. Ann Clin Lab Sci 2000; 30:85-91.
30. Mikel C, Almazan P, West R, Pesce A., West C, Latyshev S, Crews B. LC-MS/MS extends the range of drug analysis in pain patients. Ther Drug Monit 2009; 31:746-748.
31. Microgenics Corp. DRI Applications - Olympus AU640. 46360 Fremont Blvd., Fremont, CA 94538 USA.
32. Federal Register /Vol. 69, No. 71 /Tuesday, April 13, 2004 Mandatory Guidelines and Proposed Revisions to Mandatory Guidelines for Federal Workplace Drug Testing Programs; Notices Section 2.4 Laboratory Analysis Procedures (f) (1) confirmatory drug test.
33. Analysis of Opiates using the Agilent 6410 Triple Quadrupole LC/MS/MS Oregon Medical Laboratories Contact: Grant D. Yanan Yang Agilent Technologies, Inc. Santa Clara, CA Agilent reference QQQ_OML_Opiates_20070625.
34. State of New York Dept. of Health. Analytical Toxicology Proficiency Testing Program, 2008-2009. Wadsworth Center, Governor Nelson A. Rockefeller Empire State Plaza, Albany, NY.
35. AACC/CAP. 2009 Surveys and Anatomic Pathology Education Programs In: Pathologists CoA, ed: College of American Pathologists; Chicago, 2009. p.80.
36. Cone EJ, Caplan YH, Black DL, Moser F. Urine drug testing of chronic pain pa-tients: Licit and illicit drug patterns. J Anal Toxicol 2008; 32:530-543.
37. Mitchell J. NLCP Implementation of the Revised Mandatory Guidelines 2010. 2009; http://74.125.95.132/search?q=cache: i6RiZRr5-2oJ: https://nac.samhsa.gov/DTAB/Presentations/June09/JohnMitchellPTDTAB06.02-508.ppt+nlcp+guidelines&cd=4&hl=en&ct=clnk&gl=us. Accessed 10/20/2009.
38. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician 2008; 11:S181-S200.
39. Kan D. Medication Diversion Reduction 2009; www.csam-asam.org/pdf/misc/slides_Kan_Reducing_Diversion_of_Medication.pdf. Accessed 10/20/2009.
40. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11:S133-S153.
41. Smith HS. Peripherally-acting opioids. Pain Physician 2008; 11:S121-S132.
42. Patel V, Manchikanti L, Singh V, Schultz DM, Hayek SM, Smith HS. Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician 2009; 12:345-360
43. Wu A, McKay C. Recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department Clinical Chemistry 2003; 49:357-379.
44. National Prescription Drug Threat Assessment 2009. www.usdoj.gov/ndic/pubs33/33775/33775p.pdf. Accessed 8/18/09.
45. Results from the 2007 National Survey on Drug Use and Health: http://oas.samhsa.gov/nsduh/2k7nsduh/2k7Results.pdf. Accessed 8/18/09.
46. Jung B, Reidenberg MM. Physicians being deceived. Pain Med 2007; 8:433-437.